Your browser doesn't support javascript.
loading
New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
Fanella, Gaia; Baiata, Claudio; Candeloro, Elisa; Toscano, Gianpaolo; Colnaghi, Silvia; Mauri, Marco; Cariddi, Lucia Princiotta; Rebecchi, Valentina; Solazzo, Francesca; Banfi, Paola; Piatti, Marialuisa; Ferrarese, Carlo; Versino, Maurizio.
Afiliación
  • Fanella G; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy. gaiafanella@gmail.com.
  • Baiata C; School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. gaiafanella@gmail.com.
  • Candeloro E; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Toscano G; School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Colnaghi S; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Mauri M; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Cariddi LP; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Rebecchi V; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Solazzo F; DMC, University of Insubria, Varese, Italy.
  • Banfi P; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Piatti M; Clinical and Experimental Medicine and Medical Humanities, Center of Research in Medical Pharmacology, University of Insubria, Varese, Italy.
  • Ferrarese C; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
  • Versino M; Neurology and Stroke Unit, Circolo Hospital ASST Sette Laghi, Varese, Italy.
Neurol Sci ; 43(10): 5799-5802, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35870026
BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease that targets acetylcholine receptor (AChR) of the neuromuscular junction. New-onset MG after SARS-CoV-2 vaccination has rarely been reported. CASE PRESENTATION: We report about three patients who presented new-onset myasthenia gravis after receiving mRNA SARS-CoV-2 vaccination. The patients were all males and older than 55 years. All the patients presented with ocular and bulbar symptoms. The interval between vaccine administration and MG onset ranged from 3 days after the first dose to 10 days after the second dose. All the patients had elevated serum AChR antibodies and responded to pyridostigmine. Two out of three patients were successfully treated with IVIG or plasma exchange and with long-term immunosuppression. CONCLUSIONS: MG is a rare disease; clinicians should be aware of possible new-onset MG after SARS-CoV-2 vaccination, especially with the current recommendation of booster doses. The hyperstimulation of the innate immune system or the exacerbation of a subclinical pre-existing MG could be possible explanations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 / Miastenia Gravis Tipo de estudio: Guideline Límite: Aged80 / Humans / Male / Middle aged Idioma: En Revista: Neurol Sci Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 / Miastenia Gravis Tipo de estudio: Guideline Límite: Aged80 / Humans / Male / Middle aged Idioma: En Revista: Neurol Sci Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia